Alzheimer’s: Drugs help manage symptoms
Alzheimer’s still has no cure, but two types of drugs can help manage symptoms of the disease.
Alzheimer’s drugs might be one strategy to help slow or manage memory loss, thinking and reasoning problems, and day-to-day function. While Alzheimer’s drugs don’t cure the disease, they can improve quality of life and help prolong independence.
There are two types of medications approved to treat Alzheimer’s: those that can temporarily ease some symptoms, and those that can slow the progression of the disease. Medications don’t work for everyone, and they may lose effectiveness over time. They tend to be most effective for people with early to moderate Alzheimer’s.
Research into more-effective Alzheimer’s drugs is ongoing. If you can’t take the approved medications or they don’t work for you, ask your doctor if you might be eligible for a clinical trial.
Role of current Alzheimer’s drugs
The Food and Drug Administration (FDA) has approved different types of drugs specifically to treat symptoms of Alzheimer’s disease.
- Cholinesterase inhibitors
Are approved for specific Alzheimer’s stages. These stages — mild, moderate and severe — are based on scores on tests that assess memory, awareness of time and place, and thinking and reasoning.
Doctors might, however, prescribe Alzheimer’s drugs for stages other than those for which the FDA has approved them. Alzheimer’s stages aren’t exact, individual responses to drugs vary and treatment options are limited.
If your doctor prescribes medication as part of your Alzheimer’s care plan, make sure you understand the drug’s potential benefits and risks for your situation.
Are not approved for mild cognitive impairment (MCI). This condition, which involves subtle changes in memory and thinking, can be a transitional stage between normal age-related memory changes and Alzheimer’s disease. Many people with MCI — but not all — eventually develop Alzheimer’s or another dementia.
Clinical trials testing whether Alzheimer’s drugs might prevent progression of MCI to Alzheimer’s have generally shown no lasting benefit.
One way Alzheimer’s disease harms the brain is by decreasing levels of a chemical messenger (acetylcholine) that’s important for alertness, memory, thought and judgment. Cholinesterase (ko-lin-ES-tur-ays) inhibitors boost the amount of acetylcholine available to nerve cells by preventing its breakdown in the brain.
Cholinesterase inhibitors can’t reverse Alzheimer’s disease or stop the destruction of nerve cells. These medications eventually lose effectiveness because dwindling brain cells produce less acetylcholine as the disease progresses.
Common side effects can include nausea, vomiting and diarrhea. Starting treatment at a low dose and working up to a higher dose can help reduce side effects. Taking these medications with food also might help minimize side effects.
People with certain types of cardiac arrhythmias shouldn’t take cholinesterase inhibitors.
Three cholinesterase inhibitors are commonly prescribed:
- Donepezil (Aricept) is approved to treat all stages of the disease. It’s taken once a day as a pill.
- Galantamine (Razadyne) is approved to treat mild to moderate Alzheimer’s. It’s taken as a pill once a day or as an extended-release capsule twice a day.
- Rivastigmine (Exelon) is approved for mild to moderate Alzheimer’s disease. It’s taken as a pill. A skin patch is available that can also be used to treat severe Alzheimer’s disease.
Memantine for later stages
Memantine (Namenda) is approved by the FDA for treatment of moderate to severe Alzheimer’s disease. It works by regulating the activity of glutamate, a messenger chemical widely involved in brain functions — including learning and memory. It’s taken as a pill or syrup. Common side effects include dizziness, headache, confusion and agitation.
The FDA has also approved a combination of donepezil and memantine (Namzaric), which is taken as a capsule. Side effects include headache, dizziness, nausea and diarrhea.
When to discontinue Alzheimer’s drugs
Because Alzheimer’s is a progressive disease, your symptoms and care plan will change over time. If you’re taking an Alzheimer’s drug, ongoing review of your care plan will include working with your doctor to decide how long you should continue your medication.
Because the effects of Alzheimer’s drugs are usually modest, it might be difficult to tell if the drugs are working. However, you can’t know if your symptoms might be more severe without your medication.
Talk to your doctor before stopping an Alzheimer’s drug, and let your doctor know if your condition worsens after you stop.
Working with your health care team can help you find the best strategies to manage your symptoms and prolong your independence.
This intravenous infusion therapy is the first drug of its kind to be approved for Alzheimer’s disease. It is approved only for patients with mild cognitive impairment and mild dementia due to Alzheimer’s disease.
The FDA approved aducanumab under an accelerated approval provision because it reduced brain beta-amyloid, a protein that is thought to be a key part of the Alzheimer disease pathway.
However, the benefits on daily functioning, thinking or memory aren’t clear. Side effects can include:
- Amyloid related imaging abnormalities-edema (ARIA-E), in which the brain swells (edema)
- Amyloid related imaging abnormalities-hemosiderin deposition (ARIA-H), which includes small brain bleeds (microhemorrhage) and brain bleeding along the surface of the brain (superficial siderosis)
Repeated brain MRIs are needed to detect these changes.
Its current use is limited, because the Centers for Medicare & Medicaid Services (CMS) are working on plans to provide coverage for people with Medicare participating in CMS-approved randomized controlled trials.
In 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for people with mild Alzheimer’s disease and mild cognitive impairment due to Alzheimer’s disease.
A phase 3 clinical trial found that the medicine slowed cognitive decline in people with early Alzheimer’s disease. The medicine prevents amyloid plaques in the brain from clumping. The phase 3 trial was the largest so far to study whether clearing clumps of amyloid plaques from the brain can slow the disease.
Lecanemab is given as an IV infusion every two weeks. Your care team likely will watch for side effects and ask you or your caregiver how your body reacts to the drug.
Side effects of lecanemab include infusion-related reactions such as fever, flu-like symptoms, nausea, vomiting, dizziness, changes in heart rate and shortness of breath.
Also, people taking lecanemab may have swelling in the brain or may get small bleeds in the brain. Rarely, brain swelling can be serious enough to cause seizures and other symptoms. Also in rare instances, bleeding in the brain can cause death. The FDA recommends getting a brain MRI before starting treatment. It also recommends being monitored with brain MRIs during treatment for symptoms of brain swelling or bleeding.
People who carry a certain form of a gene known as APOE e4 appear to have a higher risk of these serious complications. The FDA recommends being tested for this gene before starting treatment with lecanemab.
If you take a blood thinner or have other risk factors for brain bleeding, talk to your health care professional before taking lecanemab. Blood-thinning medicines may increase the risk of bleeds in the brain.
More research is being done on the potential risks of taking lecanemab. Other research is looking at how effective lecanemab may be for people at risk of Alzheimer’s disease, including people who have a first-degree relative, such as a parent or sibling, with the disease.
From Mayo Clinic to your inbox
Sign up for free and stay up to date on research advancements, health tips, current health topics, and expertise on managing health. Click here for an email preview.
To provide you with the most relevant and helpful information, and understand which
information is beneficial, we may combine your email and website usage information with
other information we have about you. If you are a Mayo Clinic patient, this could
include protected health information. If we combine this information with your protected
health information, we will treat all of that information as protected health
information and will only use or disclose that information as set forth in our notice of
privacy practices. You may opt-out of email communications at any time by clicking on
the unsubscribe link in the e-mail.
Thank you for subscribing!
You’ll soon start receiving the latest Mayo Clinic health information you requested in your inbox.
Sorry something went wrong with your subscription
Please, try again in a couple of minutes
Aug. 30, 2023
- How is Alzheimer’s disease treated? National Institute on Aging. https://www.nia.nih.gov/health/how-alzheimers-disease-treated. Accessed March 24, 2022.
- Medications for memory, cognition and dementia-related behaviors. Alzheimer’s Association. https://www.alz.org/alzheimers-dementia/treatments/medications-for-memory?utm_source=google&utm_medium=search&utm_campaign=google-grants&set.custom.wt=google-grants&gclid=cj0keqjwiohibrces6np56ti1isbeiqaxxb5g7qpnhb27qtonoq-rplk1dxwihcrd9bif7u_tlujv3aaajzd8p8haq. Accessed March 24, 2022.
- Mild cognitive impairment. Alzheimer’s Association. http://www.alz.org/dementia/mild-cognitive-impairment-mci.asp. Accessed March 24, 2022.
- Press D, et al. Treatment of Alzheimer disease. https://www.uptodate.com/contents/search. Accessed March 24, 2022.
- Alzheimer disease dementia (adult). AskMayoExpert. Mayo Clinic; 2021.
- Graff-Radford J (expert opinion). Mayo Clinic. Sept. 30, 2022.
- Shi M , et al. Impact of Anti-amyloid-β Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer’s Disease: A Focus on Aducanumab and Lecanemab. Frontiers in Aging and Neuroscience. 2022; doi:10.3389/fnagi.2022.870517.
- Cummings J, et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s and Dementia. 2022; doi:10.1002/trc2.12295.
- Leqembi (approval letter). Biologic License Application 761269. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269. Accessed July 7, 2023.
- Van Dyck CH, et al. Lecanemab in early Alzheimer’s disease. New England Journal of Medicine. 2023; doi:10.1056/NEJMoa2212948.
- Leqembi (prescribing information). Eisai; 2023. http://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761269. Accessed July 10, 2023.